Ulipristal acetate: A novel pharmacological approach for the treatment of uterine fibroids

Nicoletta Biglia, Silvestro Carinelli, Antonio Maiorana, Marta D'Alonzo, Giuseppe Lo Monte, Roberto Marci

Research output: Contribution to journalArticlepeer-review

Abstract

Uterine fibroids are the most common benign tumors of the female genital tract. The management of symptomatic fibroids has traditionally been surgical; however, alternative pharmacological approaches have been proposed to control symptoms. To date, gonadotropin-releasing hormone analogs are the only available drugs for the preoperative treatment of fibroids. However, the US Food and Drug Administration recently authorized ulipristal acetate (UPA), an oral selective progesterone-receptor modulator, for the same indication. UPA is a new, effective, and well-tolerated option for the preoperative treatment of moderate and severe symptoms of uterine fibroids in women of reproductive age. According to clinical data, UPA shows several advantages: it is faster than leuprolide in reducing the fibroid-associated bleeding, it significantly improves hemoglobin and hematocrit levels in anemic patients, and it grants a significant reduction in the size of fibroids, which lasts for at least 6 months after the end of the treatment. Furthermore, UPA displays a better tolerability profile when compared to leuprolide; in fact, it keeps estradiol levels at mid follicular phase range, thereby reducing the incidence of hot flushes and exerting no impact on bone turnover. On the grounds of this evidence, the administration of 5 mg/day ulipristal acetate for 3 months is suggested for different patient categories and allows for planning a treatment strategy tailored to meet an individual patient's needs.

Original languageEnglish
Pages (from-to)285-292
Number of pages8
JournalDrug Design, Development and Therapy
Volume8
DOIs
Publication statusPublished - Feb 20 2014

Keywords

  • Medical treatment of uterine fibroids
  • Myomas
  • Selective progesterone-receptor modulator
  • Ulipristal acetate
  • Uterine fibroids

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Ulipristal acetate: A novel pharmacological approach for the treatment of uterine fibroids'. Together they form a unique fingerprint.

Cite this